期刊文献+

1999/2002年医院感染细菌的流行病学调查 被引量:10

Epidemiological study on pathogenic bacteria in the nosocomial infection from 1999 to 2002
下载PDF
导出
摘要 目的 :了解医院感染致病菌菌谱及耐药性动态变化 ,为临床经验性治疗细菌感染性疾病提供依据 .方法 :药敏试验用K B纸片法 ,根据NCCLS标准判断结果 ,应用WHONET 5软件对临床分离细菌的药敏结果进行统计 .结果 :1 999/ 2 0 0 2年医院感染的致病菌以G 杆菌为主 ,对所监测的 1 6种抗菌药物均不同程度耐药 ;耐甲氧西林金黄色葡萄球菌 (methicillin resistantStaphylococcusaureus,MRSA) ,耐甲氧西林表皮葡萄球菌 (methicillin resistantStaphylococcusepi dermidis,MRSE) ,和产超广谱 β内酰胺酶 (extended spec trumbeta lactamases,ESBLs)细菌耐药率明显增加 ,MRSA ,MRSE和产ESBLs细菌的比例及耐药性均无明显变化 .结论 :MRSA ,MRSE和产ESBLs细菌耐药率明显增加的情况 。 AIM: To investigate the dynamic changes in the distribution and resistance of bacilli responsible for the nosocomial infection and to offer a basis for the empirical treatment of bacterial infection. METHODS: K B test was used for the antibiotics susceptivity test and the results were recorded based on National Committee for Clinical Laboratory Standards (NCCLS) and analyzed with WHONET 5 software. RESULTS: The pathogens responsible for the nosocomial infection were mainly Gram negative bacteria during the 4 years from 1999 to 2002. They were resistant to 16 kinds of studied antibiotics. The resistant rate of methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE) and extended spectrum beta lactamases (ESBLs) producing strains markedly increased, but there were no obvious changes in the distribution and resistance of those pathogens mentioned above. CONCLUSION: The resistant rate of MSRA,MSRE and ESBLs-producing bacilli has increased markedly.
出处 《第四军医大学学报》 北大核心 2004年第10期912-914,共3页 Journal of the Fourth Military Medical University
关键词 医院感染 抗菌药物 耐药性 nosocomial infection antibiotics resistance
  • 相关文献

参考文献6

二级参考文献48

  • 1汪复,张敬德,朱德妹,王宇倩,周乐,张婴元.Du6859a及其他新的氟喹诺酮类药物的体外抗菌活性[J].中国抗生素杂志,1996,21(3):214-219. 被引量:13
  • 2Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides[J]. Drugs, 1996, 51(suppl 1):20-30
  • 3Pechere JC. Streptogramins-a unique class of antibiotics[J]. Drugs 1996, 51(suppl 1): 13-19
  • 4Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium[J]. J.Antimicrob Chemother, 1999, 44: 251-261
  • 5Diekema DI, Jones RN. Oxazolidinones: a review[J]. Drugs, 2000, 59: 7-16
  • 6Rubinstein E, Cammarata SK, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind multicenter study[J]. Clin Inf Dis, 2001, 32: 402-412
  • 7Parenti F, Schito GC, Courvalin P. Teicoplanin: Chemistry and microbiology[J]. J Chemoth, 2000, 12(suppl 5): 5-14
  • 8Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection[J]. J Chemother, 2000, 12(suppl 5): 26-33
  • 9Noviello S, Ianniello F, Esposito S. et al. In vitro activity of LY333328(oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci[J]. J Antimicrob Chemother, 2001, 48: 283-286
  • 10Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis[J]. Clin Inf Dis, 1999, 29: 239-44

共引文献1103

同被引文献60

引证文献10

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部